A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
for Systemic Lupus Erythematosus (With and Without Nephritis)
12 locations incl. Phoenix
Sponsor: Allogene Therapeutics
Sex: All·Age: 18 - 69
Code: NCT07085104·Phase 1·Recruiting